Table 2.

 Rates of response over the study period in the phosphatidylcholine (PC) and placebo groups

Treatment group	PC group (n = 30)	Placebo group (n = 30)	p Value*
Primary end point analysis
Clinical remission/improvement (⩾50%)			<0.0001
Yes	27	3
No	3	27
Clinical remission (CAI ⩽3)			0.00063
Yes	16	3
No	14	27
ΔCAI (⩾50%)			<0.0001
Decreased	27	3
Unchanged	3	23
Increased	0	4
Secondary end point analysis
ΔEAI (⩾50%)			0.00016
Decreased	11	0
Unchanged	18	27
Increased	0	2
Not determined	1	1
ΔHistology score (⩾50%)			0.0067
Decreased	13	3
Unchanged	11	19
Increased	1	1
Not determined	5	7
ΔLife quality index (⩾50%)			<0.0001
Increased	16	2
Unchanged	13	28
Decreased	0	0
Not determined	1	0

CAI, clinical activity index; EAI, endoscopic activity index.

*Fisher’s exact test.